Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis
First Claim
1. A method of treating a tumor in a lymphatic system of a subject, comprising:
- administering by intravenous injection a hyaluronan nanoparticle comprising a hyaluronic acid derivative and a platinum compound to the subject with tumors in the lymphatic system, wherein the hyaluronic acid derivative comprises;
hyaluronic acid,modified histidine, andoptionally at least one of a polymer or a C4-C20 alkyl,wherein the modified histidine and the optional at least one of polymer or C4-C20 alkyl are grafted at least to primary hydroxyl groups of the hyaluronic acid, andwherein a graft ratio of the modified histidine is within 20-100%, and a graft ratio of the optional at least one of polymer or C4-C20 alkyl is within 0-40% based upon the total number of hydroxyl groups on the hyaluronic acid.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C4-C20 alkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C4-C20 alkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.
11 Citations
21 Claims
-
1. A method of treating a tumor in a lymphatic system of a subject, comprising:
-
administering by intravenous injection a hyaluronan nanoparticle comprising a hyaluronic acid derivative and a platinum compound to the subject with tumors in the lymphatic system, wherein the hyaluronic acid derivative comprises; hyaluronic acid, modified histidine, and optionally at least one of a polymer or a C4-C20 alkyl, wherein the modified histidine and the optional at least one of polymer or C4-C20 alkyl are grafted at least to primary hydroxyl groups of the hyaluronic acid, and wherein a graft ratio of the modified histidine is within 20-100%, and a graft ratio of the optional at least one of polymer or C4-C20 alkyl is within 0-40% based upon the total number of hydroxyl groups on the hyaluronic acid. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
-
Specification